1Sakamoto J, Clin K, Kondo K, et al. Phase I1 study of a 4-week capecitabine regimen in advanced or recurrent gastric cancer [J].Anticancer Drugs,2006;17 (2): 231-6.
2Hong YS, Song SY, Lee SI, et al. A phase II trail of capecitabine in previously untreated patients with advanced and/or metastatic gastric cancer [J].Ann Oncol, 2004;15(9) : 1344-7.
3Schuller J, Cassidy J, Dumont E, et al. Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients [J]. Cancer Chemother Pharmacol, 2000:45(4) :291-7.
5Sileri P, Dugo S, Bennavoli D,et al. Metachronous splenicmetastasis from colonic carcinoma five years after surgery : a case report and literature review[ J]. South Med J ,2009 ; 102 (7) :733-5.
6Kweekel DM. Antonini NF. Nortier JW, et al. Explorative study to identify novel candidate genes related to oxaliplatin efficacy and toxicity using a DNA repair array[ J]. Br J Cancer, 2009;101(2) :357-62.
3Abushullaih S,Saad ED,MunselIM,et al.Incidence and severity of hand foot syndrome in colorectal cancer patients treated with capecitabine:a single-in stitution experience[J].CANCER INVEST,2002,20(5):3.
4de Gramont A,Seymour M,et al.Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer[J].J Clin Oncol,2000,18(16):2938.
5Scheithauer W,Kornek GV,Raderdr M,et al.Randomized multieenter phase Ⅱ trial of two different schedules of capecitabine plus oxaliplatin as first-line treatment in advanced colorectal cancer[J].J Clin Oncol,2003,21(7):1307-1312.
6Twelves C.Can capecitabine replace 5-Fu/leucovorin in combination with oxaliplatin for the treatment of advanced coloreetal cancer,Oncology(Huntingt),2002,16(12 supply NO 14):23-26.
7Sakamoto J, Clink, Kondo K, et al. Phase Ⅱ study of a 4-week capecitabineregimen in advanced or recurrent gastric cancer [JJ. Anticancer Drugs, 2006, 17 (2): 231-236.
8Hong YS, Song SY, Lee SI, et al. A phase Ⅱ trail of capecitabine in previously untreated patients with advanced and/or metastatic gastric cancer [J]. Ann Oncol, 2004, 15 (9): 1344-1347.
9Schuller J, Cassidy J, Dumont E, et al. Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients[ J]. Cancer Chemother Pharmacol, 2000, 45 (4): 291-297.
10Cassidy J, Tabernero J, Twelves C, et al. XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer [J]. J Clin Oncol, 2004, 22 ( 11): 2084-2091.
8Malet-Martino M, Martino R. Clinical studies of three oral prodrugs of 5-fluorouracil (capecitabine, UFT, S- 1 ) : a review [ J ]. The Oncologist, 2002,7 : 288-323.
9Tanaka F, Fukuse T, Wada H, et al. The history,mechanism and clinical use of oral 5-fluorouracil derivative chemotherapeutic agants [J]. Curr Pharm Biotechnol, 2000,1(2):137-164.
10Koizumi W, kurihara M, Nakano S, et al. Phase II study of S-1,a novel oral derivative of 5-fluorouracil,in advanced gastric cancer [J]. Oncology, 2000,58(3):191-197.
